Sensei Biotherapeutics, Inc. appointed William (Bill) Ringo, MBA, as chair of its board of directors and as a member of the Company's compensation committee and nominating and corporate governance committee. Mr. Ringo will serve as a Class I director whose term will expire at the 2022 annual meeting of stockholders. Mr. Ringo has over 40 years of experience in the pharmaceutical and biotechnology sectors.

Ringo was previously senior vice president of strategy and business development for Pfizer and served on its executive committee before his retirement in 2010. Ringo spent nearly 30 years at Eli Lilly and Company, holding multiple executive roles, including product group president for oncology and critical care, president of internal medicine products, president of the infectious disease business unit and vice president of sales and marketing for U.S. pharmaceuticals. Ringo also served as president and chief executive officer of Abgenix, and held advisor roles at both Barclays Capital and Sofinnova Ventures.

Mr. Ringo currently chairs the board of directors of Assembly Biosciences, Inc., and has previously served on the boards of Dermira, Five Prime Therapeutics, Immune Design, Mirati Technologies, Onyx Pharmaceuticals and Sangamo Biosciences.